Screener
Stoke Therapeutics, Inc. STOK License — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Stoke Therapeutics, Inc.’s 10-K, filed March 16, 2026.
- Filed
- Mar 16, 2026, 4:15 PM EDT
- Fiscal year
- FY2025
- Accession
- 0001193125-26-108362
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 |
|---|---|---|
| Revenue | $184,420 | $36,555 |
| Operating expenses: | ||
| Research and development | 137,922 | 89,133 |
| Sales, general and administrative | 67,088 | 48,794 |
| Total operating expenses | 205,010 | 137,927 |
| Loss from operations | (20,590) | (101,372) |
| Other income (expense): | ||
| Interest income (expense), net | 13,756 | 12,638 |
Item 16. Form 10-K Summary
FAQ
- What is Stoke Therapeutics, Inc.'s license — revenue?
- Stoke Therapeutics, Inc. (STOK) reported license — revenue of $2.88M in Q4 2025.
- How has Stoke Therapeutics, Inc.'s license — revenue changed year-over-year?
- Stoke Therapeutics, Inc.'s license — revenue decreased by 60.9% year-over-year, from $7.35M to $2.88M.
- What does license — revenue mean?
- This metric represents the total revenue recognized from licensing agreements, including upfront payments, milestone payments, and royalties derived from the company's proprietary technology platforms or intellectual property. It reflects the commercial success of the company's strategy to monetize its research and development assets through strategic partnerships with other pharmaceutical or biotechnology entities. Monitoring this revenue stream provides insight into the company's ability to generate non-dilutive capital and validate its scientific approach through external collaboration.
Ask your AI about Stoke Therapeutics, Inc.'s license — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude